[
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Files sNDA For Oral VENCLEXTA Combo Regimen In CLL Treatment",
    "summary": "AbbVie (ABBV) recently submitted a Supplemental New Drug Application to the FDA for a new combination regimen targeting chronic lymphocytic leukemia, which accompanies positive Phase 3 trial outcomes. This development aligns with AbbVie's broader strategy of expanding its oncology pipeline, potentially influencing investor perception positively. Over the past month, AbbVie's share price rose by 3.4%, bolstered by the positive trial results and submission news. This move aligns with broader...",
    "url": "https://finnhub.io/api/news?id=5f8f0513b68ff5680fffe4130be16ed2968e4079941dfd2345b4473300ff52a3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753811598,
      "headline": "AbbVie (ABBV) Files sNDA For Oral VENCLEXTA Combo Regimen In CLL Treatment",
      "id": 136129753,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) recently submitted a Supplemental New Drug Application to the FDA for a new combination regimen targeting chronic lymphocytic leukemia, which accompanies positive Phase 3 trial outcomes. This development aligns with AbbVie's broader strategy of expanding its oncology pipeline, potentially influencing investor perception positively. Over the past month, AbbVie's share price rose by 3.4%, bolstered by the positive trial results and submission news. This move aligns with broader...",
      "url": "https://finnhub.io/api/news?id=5f8f0513b68ff5680fffe4130be16ed2968e4079941dfd2345b4473300ff52a3"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=d92e74ea75c09f14230dbd0ff25f882e2e4951fec1cbfb5ea27a49483d400293",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753806660,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 136167915,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=d92e74ea75c09f14230dbd0ff25f882e2e4951fec1cbfb5ea27a49483d400293"
    }
  },
  {
    "ts": null,
    "headline": "Top 10 Income Funds From Eaton Vance",
    "summary": "Discover Eaton Vance's top closed-end funds offering reliable income, strong returns, and expert management.",
    "url": "https://finnhub.io/api/news?id=8631559f9b027ff706c53da911587e5a8550424ceb2a9df9c8c05aafe8d72e66",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753802603,
      "headline": "Top 10 Income Funds From Eaton Vance",
      "id": 136122033,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2188377987/image_2188377987.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Discover Eaton Vance's top closed-end funds offering reliable income, strong returns, and expert management.",
      "url": "https://finnhub.io/api/news?id=8631559f9b027ff706c53da911587e5a8550424ceb2a9df9c8c05aafe8d72e66"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?",
    "summary": "Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=a400422a5bfc781db71af7ceb98e681df9fe28ef887027c7bccbaf4fd8623062",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753797627,
      "headline": "Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?",
      "id": 136119190,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=a400422a5bfc781db71af7ceb98e681df9fe28ef887027c7bccbaf4fd8623062"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA速 (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)",
    "summary": "AbbVie (NYSE: ABBV) announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the fixed-duration, all-oral combination regimen of VENCLEXTA速 (venetoclax) and acalabrutinib in previously untreated patients with CLL, offering CLL patients another VENCLEXTA combination regimen with the potential for time-limited treatment.The submission is based on the positive results from the Phase 3 AMPLIFY trial.1 The combination regimen of VENCLEX",
    "url": "https://finnhub.io/api/news?id=2dbc846f2df8e414d8b1d7aff61c50cd79e582bf752188229493511cbc7c3621",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753790400,
      "headline": "AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA速 (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)",
      "id": 136117000,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the fixed-duration, all-oral combination regimen of VENCLEXTA速 (venetoclax) and acalabrutinib in previously untreated patients with CLL, offering CLL patients another VENCLEXTA combination regimen with the potential for time-limited treatment.The submission is based on the positive results from the Phase 3 AMPLIFY trial.1 The combination regimen of VENCLEX",
      "url": "https://finnhub.io/api/news?id=2dbc846f2df8e414d8b1d7aff61c50cd79e582bf752188229493511cbc7c3621"
    }
  }
]